Arcutis Biotherapeutics, Inc.
ARQT
Rank in Stocks
#3998
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Share Price
$32.29
Market Cap
$4.06B
Change (1 day)
12.02%
Change (1 year)
54.62%
Country
US
Trade Arcutis Biotherapeutics, Inc. (ARQT)
Category
Healthcare
Earnings for Arcutis Biotherapeutics, Inc. (ARQT)
Earnings in Jun 2026 TTM: $29.30M
According to Arcutis Biotherapeutics, Inc. latest financial reports the company's current earnings are $29.30M. In 2023 the company made an earning of $-259.03M, an increase over its 2022 earnings that were of $-311.46M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Arcutis Biotherapeutics, Inc. from 2017 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $29.30M | -121.02% |
| 2024 | $-139.39M | -46.19% |
| 2023 | $-259.03M | -16.83% |
| 2022 | $-311.46M | 50.93% |
| 2021 | $-206.36M | 52.09% |
| 2020 | $-135.68M | 223.07% |
| 2019 | $-42.00M | 118.10% |
| 2018 | $-19.26M | 286.80% |
| 2017 | $-4.98M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | 17,904.30% |
US
|
|
| $-3.09B | -10,636.56% |
US
|
|
| $-4.02B | -13,808.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 6,557.96% |
NL
|
